Table 4.
Examples of nanotechnology-based formulations in clinical trials for cancer therapy
| Type of nanomaterial | Product | Therapeutic agent | Indication | Status |
|---|---|---|---|---|
| Gold nanoparticle | Aurimmune | TNF | Solid tumour | Phase I |
| Anti-TfRscFv-decorated liposome: DOTAP, DOPE (1:1 molar ratio) | SGT-53 | Human wild-type p53 DNA | Recurrent GBM, metastatic pancreatic cancer | Phase II |
| PEG-PEI-cholesterol lipopolymer | GEN-1 | IL-12 plasmid | Epithelial ovarian, fallopian tube, and primary peritoneal cancers | Phase I/II |
| Targeted minicell | TargomiRs | miRNA mimic | Malignant pleural mesothelioma; nonsmall cell lung cancer | Phase I |
| Lipid NPs | ND-L02-s0201 | siRNA | Advanced liver fibrosis | Completed Ib/II clinical trial |
| Lipid NPs | ARB-001467 | siRNA | Hepatitis B | Completed clinical phase II studies |
| NBTXR3 | Crystalline NPs | Hafnium oxide | Soft tissue sarcoma, liver cancer, prostate adenocarcinoma, head and neck cancer, NSCLC, rectal cancer | Phase II/III |